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The central concept of precision medicine is to take individual variability into account when making 
management decisions [1].  This is likely to be particularly relevant in heterogeneous conditions such 
as COPD, the complexity of which is further multiplied by the heterogeneity of exacerbations [2].  
Whatever you want to call observable differences between patients - phenotypes or treatable traits 
[3] - understanding and quantifying these differences, for example using biomarkers, has the 
potential to bring precision medicine to those living with COPD. 
 
The history of biomarkers in COPD - defined simply as something objectively measured to inform 
prognosis or treatment response  - is not glorious.  Where is the respiratory troponin to define acute 
exacerbation?  Where is the respiratory eGFR, a calculation that has surpassed mere measurement 
of kidney function such that changes in eGFR are now used to define and stage chronic kidney 
disease?  At best we have biomarkers that may permit the use or withholding of therapy in COPD, 
including corticosteroids via assessment of eosinophils - in stable and exacerbated disease [4,5] – 
and perhaps antibiotics at exacerbation through assessment of procalcitonin [6].  Why nothing 
better? 
 
Our ability to sample the airway is certainly part of the problem.  For molecular biomarkers 
bronchoscopy is too invasive, exhaled breath condensate (EBC) insufficiently validated and sputum, 
even if the patient is producing it or can be induced, a challenging sample to work with: difficult to 
process and highly variable.  A blood marker remains analytically much more preferable, if 
potentially less lung-specific. 
 
The heterogeneity of COPD contributes to the absence of generic biomarkers too.  Was it ever likely 
that a single marker would diagnose heterogeneous exacerbations in heterogeneous patients [7]?  
Turn that around, however, and a more positive scenario arises.  Heterogeneity provides the 
possibility that a marker may be useful to predict specific outcomes in specific populations: the 
essence of precision medicine. 
 
Less obvious than the value of a biomarker in guiding individual treatment or prognosis is the 
potential value of a biomarker in the conduct of clinical trials.  Use of a biomarker to enrich a trial 
population for subjects more likely to experience the end-point of interest may mean fewer subjects 
are required, or need to be followed for a shorter time.  This increases the efficiency and reduces the 
cost of clinical research – a valuable development.  In the TORCH study [8], for example, only 14% of 
subjects experienced the primary (all cause mortality) end-point. 
 
It is in this latter context that the paper reported in this issue of the Journal [9] is important.  Miller 
and colleagues report the process through which the COPD Biomarker Qualification Consortium 
(CBQC) made a case to the FDA, subsequently accepted, around the utility of plasma fibrinogen as a 
biomarker (used in addition to clinical information) to enrich clinical trials for the key clinical end-
points of all-cause mortality and exacerbations.  The clinical outcomes have been reported 
previously [10].  In a total pool of 6376 individuals, plasma fibrinogen >350mg/dl (45% of the 
population) was associated with an increased risk for hospitalised exacerbation over 12 months 
(hazard ratio, HR 1.64; 95% confidence interval, CI: 1.39-1.93) and of all-cause mortality over 36 
months (HR: 1.94; 95% CI: 1.62-2.31).  I applaud the investment in time and money from the COPD 
Foundation, patient, academic and industry partners who completed the project.  Fibrinogen is the 
first biomarker in COPD to be assessed so rigorously and qualification makes it easier to use 
fibrinogen in this way for future studies.  The present paper will be of most interest to others 
minded to embark on such a process and the CBQC are pursuing other markers. 
 
Fibrinogen is an acute-phase glycoprotein synthesised in the liver and a key component of the blood 
coagulation system, forming (insoluble) fibrin on cleavage by thrombin.  Fibrin fibres are then cross-
linked by through the action of Factor XIII.  Plasma fibrinogen has many of the characteristics of a 
good biomarker including being relatively easy and reliable to measure in existing practice, and 
present at a reproducible concentration in stable disease. 
 
The story of fibrinogen in COPD is not new.  In 2000, Wedzicha [11] reported elevation of plasma 
fibrinogen in COPD patients compared to controls, and at COPD exacerbation compared to baseline 
– especially when exacerbations were associated with sputum purulence.  And we have known for 
some time that elevated systemic inflammation in COPD is associated with adverse outcomes [12].  
As a marker of all-cause mortality in COPD, fibrinogen is almost certainly reflecting cardiovascular 
risk.  Fibrinogen is a well-established marker of cardiovascular risk in the general population [13] so 
perhaps this is unsurprising.  Indeed, you might argue that fibrinogen isn’t a COPD biomarker at all, 
rather a marker of co-morbidity, in this case the excess cardiovascular risk observed in our patients 
with COPD. 
 
The association with future exacerbations is more interesting.  It may well be based on prior 
exacerbation events increasing vascular risk [14], or perhaps the concept that the presentation of 
exacerbation is more severe in those with underlying ischaemic heart disease [15].  Certainly in the 
absence of data to suggest that exacerbations are initiated by vascular pathology it seems unlikely 
that fibrinogen has direct mechanistic involvement and that it therefore may be a druggable target.  
Of course the best predictor of future exacerbations remains a history of past events [16]; fibrinogen 
is not offering precision medicine at an individual patient level that surpasses readily available 
clinical information.  The benefit, once again, may be in selecting subjects for recruitment to clinical 
trials. 
 
Studies are now in progress that will provide proof that biomarker based enrichment of clinical trials 
in COPD actually works.  Don't under-estimate the value in this to the respiratory community, even if 
our enthusiasm for all-cause mortality as an end-point has perhaps been tempered.  But what we 
really need, still, are better biomarkers of treatment response and prognosis in individual patients.  
Only then can we achieve our shared goal of improving the lives of all those affected by this most 
disabling condition.  We still await the era of precision medicine in COPD. 
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